Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Scand J Gastroenterol

Retrieve available abstracts of 137 articles:
HTML format



Single Articles


    June 2022
  1. KOUKI M, Caron B, Malgras A, Ayav A, et al
    Weight change after colectomy for ulcerative colitis.
    Scand J Gastroenterol. 2022 Jun 20:1-3. doi: 10.1080/00365521.2022.2089537.
    PubMed     Abstract available


  2. BAUER N, Kairey L, Schlee C, Uecker C, et al
    Use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD): results from a German nationwide survey of 2019 compared to a previous survey of 2002.
    Scand J Gastroenterol. 2022 Jun 18:1-7. doi: 10.1080/00365521.2022.2078667.
    PubMed     Abstract available


  3. PUOLANNE AM, Qadri S, Vesterinen T, Hiltunen S, et al
    Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?
    Scand J Gastroenterol. 2022 Jun 13:1-8. doi: 10.1080/00365521.2022.2084345.
    PubMed     Abstract available


    May 2022
  4. FERNANDES SR, Rodrigues IC, Serrazina J, Botto IA, et al
    Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
    Scand J Gastroenterol. 2022 May 22:1-7. doi: 10.1080/00365521.2022.2076567.
    PubMed     Abstract available


  5. MONMOUSSEAU F, Mulot L, Rusch E, Picon L, et al
    Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics.
    Scand J Gastroenterol. 2022;57:566-573.
    PubMed     Abstract available


    April 2022
  6. CHRISTENSEN KR, Ainsworth MA, Steenholdt C, Buhl S, et al
    Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics.
    Scand J Gastroenterol. 2022 Apr 12:1-7. doi: 10.1080/00365521.2022.2060049.
    PubMed     Abstract available


  7. VOLKERS A, Bossuyt P, de Jong J, Pouillon L, et al
    Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study.
    Scand J Gastroenterol. 2022;57:439-445.
    PubMed     Abstract available


  8. KIM JE, Won H, Kim YH, Kim ER, et al
    Specificity of clinical decision support tools for vedolizumab and ustekinumab in biologically naive patients with Crohn's disease.
    Scand J Gastroenterol. 2022;57:446-448.
    PubMed     Abstract available


  9. HIRSCH RD, Keung C, Con D, Vasudevan A, et al
    Direct health care costs of managing perianal Crohn's Disease in a population based cohort.
    Scand J Gastroenterol. 2022;57:432-438.
    PubMed     Abstract available


  10. YLISAUKKO-OJA T, Puttonen M, Jokelainen J, Koivusalo M, et al
    Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
    Scand J Gastroenterol. 2022;57:415-423.
    PubMed     Abstract available


  11. BRODERSEN JB, Andersen KW, Jensen MD
    Adherence to the bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn's disease and factors affecting the image quality.
    Scand J Gastroenterol. 2022;57:501-506.
    PubMed     Abstract available


  12. HERMANSON M, Bengtson J, Croix H, Lindholm E, et al
    Ileal pouch-anal anastomosis; 18 years of experience and outcomes across two generations of surgeons at a tertiary center in Sweden.
    Scand J Gastroenterol. 2022;57:401-405.
    PubMed     Abstract available


    March 2022
  13. REPO M, Pessi J, Wirtanen E, Hiltunen P, et al
    Frequency and clinical significance of histologic upper gastrointestinal tract findings in children with inflammatory bowel disease.
    Scand J Gastroenterol. 2022 Mar 31:1-5. doi: 10.1080/00365521.2022.2057197.
    PubMed     Abstract available


  14. GAO X, Huang D, Yang LS, He AQ, et al
    Identification of gut microbiome and transcriptome changes in ulcerative colitis and pouchitis.
    Scand J Gastroenterol. 2022 Mar 11:1-11. doi: 10.1080/00365521.2022.2047221.
    PubMed     Abstract available


  15. ERONEN H, Kolehmainen S, Koffert J, Koskinen I, et al
    Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study.
    Scand J Gastroenterol. 2022 Mar 3:1-6. doi: 10.1080/00365521.2022.2045350.
    PubMed     Abstract available


    February 2022
  16. MATTILA K, Rankala R, Voutilainen M, Mustonen A, et al
    Inflammatory bowel disease: perceived impact on leisure-time activities.
    Scand J Gastroenterol. 2022 Feb 23:1-6. doi: 10.1080/00365521.2022.2042593.
    PubMed     Abstract available


  17. APPEL CW, Pedersen SC, Nielsen AS, Larsen BF, et al
    Telemedicine based on patient-reported outcomes in management of patients with inflammatory bowel disease in a real-life setting - a before and after cohort study.
    Scand J Gastroenterol. 2022 Feb 23:1-7. doi: 10.1080/00365521.2022.2041083.
    PubMed     Abstract available


  18. KHERA AJ, Chase JW, Stillman BC, Salzberg M, et al
    Pelvic floor behavioral treatment for fecal incontinence and constipation in quiescent inflammatory bowel disease.
    Scand J Gastroenterol. 2022 Feb 21:1-7. doi: 10.1080/00365521.2022.2039280.
    PubMed     Abstract available


  19. WICKRAMASEKERA N, Coates E, Barr A, Lee MJ, et al
    Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment.
    Scand J Gastroenterol. 2022 Feb 10:1-10. doi: 10.1080/00365521.2022.2036808.
    PubMed     Abstract available


  20. HILON J, Alstad T, Hasseus B, Kashani H, et al
    Phenotype of Crohn's disease according to the Montreal classification in relation to dental health status.
    Scand J Gastroenterol. 2022;57:183-189.
    PubMed     Abstract available


  21. O'GRADY J, Carey BW, Kavanagh RG, O'Connell A, et al
    Making computed tomography safer for patients with Crohn's disease.
    Scand J Gastroenterol. 2022;57:175-182.
    PubMed     Abstract available


  22. ZHULINA Y, Udumyan R, Tysk C, Halfvarson J, et al
    Mortality in patients with Crohn's disease in Orebro, Sweden 1963-2010.
    Scand J Gastroenterol. 2022;57:158-164.
    PubMed     Abstract available


    January 2022
  23. JELSNESS-JORGENSEN LP, Moum B, Grimstad T, Jahnsen J, et al
    The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients.
    Scand J Gastroenterol. 2022 Jan 25:1-7. doi: 10.1080/00365521.2022.2029939.
    PubMed     Abstract available


  24. GE C, Lu Y, Shen H, Zhu L, et al
    Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis.
    Scand J Gastroenterol. 2022 Jan 7:1-12. doi: 10.1080/00365521.2021.2022193.
    PubMed     Abstract available


    December 2021
  25. WARD D, Neumann A, Hendel JW, Riis LB, et al
    Danish Society for Gastroenterology and Hepatology's clinical recommendations for colonoscopic surveillance for colorectal dysplasia and cancer in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Dec 30:1-8. doi: 10.1080/00365521.2021.2022191.
    PubMed     Abstract available


  26. DIGNASS AU, Paridaens K, Al Awadhi S, Begun J, et al
    Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.
    Scand J Gastroenterol. 2021 Dec 21:1-8. doi: 10.1080/00365521.2021.2015801.
    PubMed     Abstract available


  27. WYNNE J, Kozuch P
    Medical marijuana for inflammatory bowel disease: the highs and lows.
    Scand J Gastroenterol. 2021 Dec 17:1-9. doi: 10.1080/00365521.2021.1998604.
    PubMed     Abstract available


  28. EL-DALLAL M, Saroufim A, Systrom H, Ballou S, et al
    Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study.
    Scand J Gastroenterol. 2021 Dec 11:1-9. doi: 10.1080/00365521.2021.2013527.
    PubMed     Abstract available


  29. ZHANG M, Bai X, Zhang H, You Y, et al
    The role of cytomegalovirus colitis on short- and long-term outcomes for patients with ulcerative colitis.
    Scand J Gastroenterol. 2021 Dec 11:1-8. doi: 10.1080/00365521.2021.2006298.
    PubMed     Abstract available


  30. WALTER S, Jones MP, Sjodahl J, Stjernman H, et al
    Measuring the impact of gastrointestinal inconvenience and symptoms on perceived health in the general population - validation of the Short Health Scale for gastrointestinal symptoms (SHS-GI).
    Scand J Gastroenterol. 2021;56:1406-1413.
    PubMed     Abstract available


  31. LUNDQUIST LR, Rasmussen B, Waldorff FB, Wehberg S, et al
    Predictors of health-related quality of life in patients with Crohn's disease receiving biological therapy.
    Scand J Gastroenterol. 2021;56:1434-1441.
    PubMed     Abstract available


  32. WEI Y, Chen T, Yang W, Li H, et al
    Detection of a novel antigen for Crohn's disease.
    Scand J Gastroenterol. 2021;56:1427-1433.
    PubMed     Abstract available


  33. HAN ZM, Chen BX, Zhou Q, Liu HB, et al
    Predictors of infliximab-induced deep remission in treatment-naive patients with isolated small bowel Crohn's disease.
    Scand J Gastroenterol. 2021;56:1422-1426.
    PubMed     Abstract available


    November 2021
  34. GRIMSTAD T, Skjellerudsveen BM, Kvaloy JT, Skoie IM, et al
    The influence of disease activity on fatigue in patients with ulcerative colitis - a longitudinal study.
    Scand J Gastroenterol. 2021 Nov 30:1-8. doi: 10.1080/00365521.2021.2007281.
    PubMed     Abstract available


  35. CHRISTENSEN KR, Steenholdt C, Buhl S, Brynskov J, et al
    A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.
    Scand J Gastroenterol. 2021 Nov 13:1-8. doi: 10.1080/00365521.2021.2002397.
    PubMed     Abstract available


  36. FURUYA Y, Fukai K, Nakazawa S, Kojimahara N, et al
    Occupational physical activity differentially affects the risk for developing later-onset Crohn's disease and ulcerative colitis among middle-aged and older populations.
    Scand J Gastroenterol. 2021 Nov 11:1-8. doi: 10.1080/00365521.2021.1999495.
    PubMed     Abstract available


  37. TSUJII Y, Nishida T, Osugi N, Fujii Y, et al
    Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study.
    Scand J Gastroenterol. 2021 Nov 9:1-7. doi: 10.1080/00365521.2021.1998601.
    PubMed     Abstract available


  38. JORISSEN C, Verstockt B, Schils N, Sabino J, et al
    Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients.
    Scand J Gastroenterol. 2021;56:1323-1327.
    PubMed     Abstract available


    October 2021
  39. LINDHAGEN S, Karling P
    A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study.
    Scand J Gastroenterol. 2021 Oct 26:1-6. doi: 10.1080/00365521.2021.1993328.
    PubMed     Abstract available


  40. SHIMODAIRA Y, Watanabe K, Fukuda S, Watanabe N, et al
    Limited endoscopic mucosal inflammation on equivalent to Mayo endoscopic subscore of 0 unaffect clinical relapse of ulcerative colitis.
    Scand J Gastroenterol. 2021 Oct 18:1-4. doi: 10.1080/00365521.2021.1991467.
    PubMed     Abstract available


    September 2021
  41. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study.
    Scand J Gastroenterol. 2021 Sep 30:1-7. doi: 10.1080/00365521.2021.1983640.
    PubMed     Abstract available


  42. LEHTOMAKI J, Nikkonen A, Merras-Salmio L, Hiltunen P, et al
    Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Sep 21:1-6. doi: 10.1080/00365521.2021.1977843.
    PubMed     Abstract available


  43. ATTAUABI M, Hoglund C, Fassov J, Pedersen KB, et al
    Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
    Scand J Gastroenterol. 2021;56:1040-1048.
    PubMed     Abstract available


    August 2021
  44. VAN ERP LW, Groenen MJM, Heida W, Wisse J, et al
    Mobile application to monitor inflammatory bowel disease patients on intravenous biologic treatment: a feasibility study.
    Scand J Gastroenterol. 2021 Aug 27:1-8. doi: 10.1080/00365521.2021.1966832.
    PubMed     Abstract available


  45. LING F, Tu L, Li J, Chen Y, et al
    Psychological aspect of patients with inflammatory bowel disease, which may be related to the quality of life, sleep and disease characteristics.
    Scand J Gastroenterol. 2021 Aug 27:1-9. doi: 10.1080/00365521.2021.1966093.
    PubMed     Abstract available


  46. ERIKSSON C, Visuri I, Vigren L, Nilsson L, et al
    Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
    Scand J Gastroenterol. 2021 Aug 20:1-8. doi: 10.1080/00365521.2021.1963466.
    PubMed     Abstract available


  47. FART F, Salihovic S, McGlinchey A, Gareau MG, et al
    Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue.
    Scand J Gastroenterol. 2021 Aug 12:1-10. doi: 10.1080/00365521.2021.1961306.
    PubMed     Abstract available


  48. KIM HM, Kim JH, Lee JK, Kang DR, et al
    Age- and sex-specific risk of colorectal cancer in incident ulcerative colitis during the first 10 years after diagnosis: a nationwide population-based study.
    Scand J Gastroenterol. 2021 Aug 10:1-7. doi: 10.1080/00365521.2021.1958370.
    PubMed     Abstract available


  49. LUDVIGSSON JF, Holmgren J, Grip O, Halfvarson J, et al
    Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002-2017.
    Scand J Gastroenterol. 2021 Aug 8:1-11. doi: 10.1080/00365521.2021.1924259.
    PubMed     Abstract available


  50. RONNBLOM A, Ljunggren O, Karlbom U
    Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort.
    Scand J Gastroenterol. 2021 Aug 8:1-8. doi: 10.1080/00365521.2021.1961309.
    PubMed     Abstract available


    July 2021
  51. ANISDAHL K, Svatun Lirhus S, Medhus AW, Moum B, et al
    First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
    Scand J Gastroenterol. 2021 Jul 28:1-6. doi: 10.1080/00365521.2021.1955147.
    PubMed     Abstract available


  52. ATIA O, Gupta A, Travis S, Turner D, et al
    The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis.
    Scand J Gastroenterol. 2021 Jul 14:1-7. doi: 10.1080/00365521.2021.1947368.
    PubMed     Abstract available


  53. CHEN BX, Han ZM, Zhou Q, Liu HB, et al
    Efficacy of infliximab in treatment-naive patients with stricturing small bowel Crohn's disease.
    Scand J Gastroenterol. 2021;56:812-819.
    PubMed     Abstract available


    June 2021
  54. KOLEHMAINEN S, Ylisaukko-Oja T, Jokelainen J, Koivusalo M, et al
    Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
    Scand J Gastroenterol. 2021 Jun 21:1-8. doi: 10.1080/00365521.2021.1938206.
    PubMed     Abstract available


  55. KRISTENSEN VA, Opheim R, Perminow G, Huppertz-Hauss G, et al
    Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway.
    Scand J Gastroenterol. 2021 Jun 21:1-7. doi: 10.1080/00365521.2021.1922746.
    PubMed     Abstract available


  56. SIPPONEN T, Af Bjorkesten CG, Hallinen T, Ilus T, et al
    A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland.
    Scand J Gastroenterol. 2021;56:661-670.
    PubMed     Abstract available


  57. FORSS A, Clements M, Myrelid P, Strid H, et al
    Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
    Scand J Gastroenterol. 2021;56:680-686.
    PubMed     Abstract available


  58. ROOSENBOOM B, Horjus Talabur Horje CS, Smids C, Leeuwis JW, et al
    Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies.
    Scand J Gastroenterol. 2021;56:671-679.
    PubMed     Abstract available


    May 2021
  59. LOPEZ-SERRANO A, Suarez MJ, Beso P, Algarra A, et al
    Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease: a case-control study.
    Scand J Gastroenterol. 2021 May 27:1-9. doi: 10.1080/00365521.2021.1925339.
    PubMed     Abstract available


  60. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
    Physical exercise is associated with beneficial bone mineral density and body composition in young adults with childhood-onset inflammatory bowel disease.
    Scand J Gastroenterol. 2021 May 4:1-9. doi: 10.1080/00365521.2021.1913759.
    PubMed     Abstract available


    April 2021
  61. RUBIN DE CELIX C, Chaparro M, Moreno JA, Santander C, et al
    Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience.
    Scand J Gastroenterol. 2021 Apr 27:1-6. doi: 10.1080/00365521.2021.1918758.
    PubMed     Abstract available


  62. VAN DER GIESSEN J, Fuhler GM, van der Woude CJ
    A first pregnancy seems associated with a positive effect on the course of inflammatory bowel disease: data from a prospective pregnancy cohort.
    Scand J Gastroenterol. 2021 Apr 20:1-6. doi: 10.1080/00365521.2021.1910996.
    PubMed     Abstract available


  63. RANKALA R, Mattila K, Voutilainen M, Mustonen A, et al
    Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism.
    Scand J Gastroenterol. 2021 Apr 7:1-6. doi: 10.1080/00365521.2021.1908416.
    PubMed     Abstract available


  64. BROMS G, Soderling J, Sachs MC, Halfvarson J, et al
    Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study.
    Scand J Gastroenterol. 2021;56:410-421.
    PubMed     Abstract available


  65. SINGH H, Nguyen T, Pho C, Giles E, et al
    Early Infliximab in Crohn's is associated with decreased intestinal surgery and similar health care costs.
    Scand J Gastroenterol. 2021;56:397-402.
    PubMed     Abstract available


    March 2021
  66. MOUM KM, Moum B, Opheim R
    Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
    Scand J Gastroenterol. 2021 Mar 26:1-7. doi: 10.1080/00365521.2021.1901308.
    PubMed     Abstract available


  67. BEKIC D, Belosic Halle Z
    Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
    Scand J Gastroenterol. 2021 Mar 25:1-5. doi: 10.1080/00365521.2021.1902561.
    PubMed     Abstract available


  68. QVIST N, Vadstrup K, Alulis S, Borsi A, et al
    Increased use of biologics in the era of TNF-alpha inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based st
    Scand J Gastroenterol. 2021 Mar 18:1-8. doi: 10.1080/00365521.2021.1897670.
    PubMed     Abstract available


  69. BONNAUD G, Haennig A, Altwegg R, Caron B, et al
    Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI((R)) on quality of life and quality of care in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Mar 10:1-7. doi: 10.1080/00365521.2021.1894602.
    PubMed     Abstract available


  70. ARBOGAST JP, Urbanik S, Schmidt R, Mennigen R, et al
    Impact of the Crohn's disease digestive damage score (Lemann Index) on the perioperative course in patients with Crohn's disease and ileocolic anastomosis.
    Scand J Gastroenterol. 2021;56:239-246.
    PubMed     Abstract available


    February 2021
  71. ANKERSEN DV, Weimers P, Marker D, Teglgaard Peters-Lehm C, et al
    Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up-a Danish register-based study.
    Scand J Gastroenterol. 2021 Feb 28:1-10. doi: 10.1080/00365521.2021.1892176.
    PubMed     Abstract available


  72. RONNBLOM A, Karlbom U
    Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort.
    Scand J Gastroenterol. 2021 Feb 12:1-7. doi: 10.1080/00365521.2021.1882553.
    PubMed     Abstract available


    January 2021
  73. ERONEN H, Ilus T, Jussila A, Huhtala H, et al
    Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids.
    Scand J Gastroenterol. 2021 Jan 26:1-8. doi: 10.1080/00365521.2020.1867892.
    PubMed     Abstract available


  74. ATTAUABI M, Burisch J, Seidelin JB
    Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.
    Scand J Gastroenterol. 2021;56:53-58.
    PubMed     Abstract available


  75. YANG Y, Cui X, Li J, Wang H, et al
    Clinical evaluation of vitamin D status and its relationship with disease activity and changes of intestinal immune function in patients with Crohn's disease in the Chinese population.
    Scand J Gastroenterol. 2021;56:20-29.
    PubMed     Abstract available


    December 2020
  76. DORE MP, Fanciulli G, Manca A, Cocco V, et al
    Clinically relevant thyroid disorders and inflammatory bowel disease are inversely related: a retrospective case-control study.
    Scand J Gastroenterol. 2020 Dec 16:1-6. doi: 10.1080/00365521.2020.1861323.
    PubMed     Abstract available


  77. XI W, Li Z, Ren R, Sai XY, et al
    Effect of antibiotic therapy in patients with ulcerative colitis: a meta-analysis of randomized controlled trials.
    Scand J Gastroenterol. 2020 Dec 12:1-9. doi: 10.1080/00365521.2020.1858958.
    PubMed     Abstract available


  78. DE JONG ME, Taal E, Thomas PWA, Romkens TEH, et al
    Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Dec 10:1-7. doi: 10.1080/00365521.2020.1857430.
    PubMed     Abstract available


  79. STRIK AS, Lowenberg M, Mould DR, Berends SE, et al
    Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
    Scand J Gastroenterol. 2020 Dec 8:1-10. doi: 10.1080/00365521.2020.1856405.
    PubMed     Abstract available


  80. OSTLUND I, Werner M, Karling P
    Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Dec 7:1-8. doi: 10.1080/00365521.2020.1854342.
    PubMed     Abstract available


  81. KRISTJANSSON VB, Lund SH, Grondal G, Sveinsdottir SV, et al
    Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018.
    Scand J Gastroenterol. 2020 Dec 5:1-7. doi: 10.1080/00365521.2020.1854847.
    PubMed     Abstract available


    November 2020
  82. LAMERS CR, de Roos NM, Bongers CCWG, Ten Haaf DSM, et al
    Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Nov 19:1-8. doi: 10.1080/00365521.2020.1845791.
    PubMed     Abstract available


  83. KRISHNAPRASAD K, Walsh A, Begun J, Bell S, et al
    Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Nov 8:1-8. doi: 10.1080/00365521.2020.1839960.
    PubMed     Abstract available


  84. WALENTYNOWICZ M, Van de Pavert I, Coenen S, Fierens L, et al
    Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium - a validation of the Dutch rating form.
    Scand J Gastroenterol. 2020 Nov 1:1-6. doi: 10.1080/00365521.2020.1839962.
    PubMed     Abstract available


    October 2020
  85. ANKERSEN DV, Weimers P, Marker D, Johannesen T, et al
    eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis.
    Scand J Gastroenterol. 2020 Oct 12:1-10. doi: 10.1080/00365521.2020.1829031.
    PubMed     Abstract available


    September 2020
  86. PETTERSSON N, Kragsbjerg F, Hamrin A, Bergman S, et al
    Increased chronic pain in patients with ulcerative colitis is mostly associated to increased disease activity. A cross-sectional case-control study.
    Scand J Gastroenterol. 2020 Sep 18:1-7. doi: 10.1080/00365521.2020.1820567.
    PubMed     Abstract available


    August 2020
  87. LO B, Vind I, Vester-Andersen MK, Burisch J, et al
    Validation of ulcerative colitis and Crohn's disease and their phenotypes in the Danish National Patient Registry using a population-based cohort.
    Scand J Gastroenterol. 2020 Aug 24:1-5. doi: 10.1080/00365521.2020.1807598.
    PubMed     Abstract available


  88. VIOLA A, Fontana A, Belvedere A, Scoglio R, et al
    Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach.
    Scand J Gastroenterol. 2020 Aug 24:1-9. doi: 10.1080/00365521.2020.1807599.
    PubMed     Abstract available


  89. SILVA JC, Fernandes C, Rodrigues J, Fernandes S, et al
    Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis.
    Scand J Gastroenterol. 2020 Aug 8:1-6. doi: 10.1080/00365521.2020.1803397.
    PubMed     Abstract available


  90. MALICKOVA K, Kratka Z, Luxova S, Bortlik M, et al
    Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?
    Scand J Gastroenterol. 2020;55:917-919.
    PubMed     Abstract available


    July 2020
  91. ARIEIRA C, Dias de Castro F, Curdia Goncalves T, Moreira MJ, et al
    Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?
    Scand J Gastroenterol. 2020 Jul 20:1-4. doi: 10.1080/00365521.2020.1792543.
    PubMed     Abstract available


  92. KARJALAINEN EK, Renkonen-Sinisalo L, Lepisto AH
    Dysplasia in the mucosal biopsy specimen is still a warning sign of cancer in ulcerative colitis.
    Scand J Gastroenterol. 2020 Jul 16:1-5. doi: 10.1080/00365521.2020.1794024.
    PubMed     Abstract available


  93. WHITE JR, Din S, Ingram RJM, Foley S, et al
    Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study.
    Scand J Gastroenterol. 2020 Jul 11:1-10. doi: 10.1080/00365521.2020.1790647.
    PubMed     Abstract available


  94. ALEKNONYTE-RESCH M, Freitag-Wolf S, Schreiber S, Krawczak M, et al
    Case-only analysis of gene-gene interactions in inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jul 10:1-10. doi: 10.1080/00365521.2020.1790646.
    PubMed     Abstract available


  95. VAN DER SLOOT KWJ, Voskuil MD, Visschedijk MC, Festen EAM, et al
    Latent cytomegalovirus infection does not influence long-term disease outcomes in inflammatory bowel disease, but is associated with later onset of disease.
    Scand J Gastroenterol. 2020 Jul 7:1-6. doi: 10.1080/00365521.2020.1786853.
    PubMed     Abstract available


  96. BUHL S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, et al
    Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jul 6:1-7. doi: 10.1080/00365521.2020.1786852.
    PubMed     Abstract available


    June 2020
  97. SENGUPTA NK, Azizov A, Halder S, Xenodemetropoulos T, et al
    Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jun 23:1-6. doi: 10.1080/00365521.2020.1780470.
    PubMed     Abstract available


  98. XU Y, Xu F, Li W, Li M, et al
    The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jun 22:1-8. doi: 10.1080/00365521.2020.1781926.
    PubMed     Abstract available


  99. MAGDZIAK A, Szlak J, Mroz A, Wieszczy P, et al
    A stool test in patients with active ulcerative colitis helps exclude cytomegalovirus disease.
    Scand J Gastroenterol. 2020 Jun 19:1-7. doi: 10.1080/00365521.2020.1771760.
    PubMed     Abstract available


  100. JUDGE C, McGettigan N, Ryan T, Hazel K, et al
    Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jun 16:1-9. doi: 10.1080/00365521.2020.1779340.
    PubMed     Abstract available


  101. WEN Y, Niu J, Zhang F, Wu J, et al
    Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis.
    Scand J Gastroenterol. 2020 Jun 13:1-10. doi: 10.1080/00365521.2020.1774924.
    PubMed     Abstract available


  102. FRIMOR C, Kjeldsen J, Ainsworth M
    Treatment to target in patients with inflammatory bowel disease. What is the evidence?
    Scand J Gastroenterol. 2020 Jun 5:1-9. doi: 10.1080/00365521.2020.1764091.
    PubMed     Abstract available


    May 2020
  103. ROSA I, Silva P, da Mata S, Magro F, et al
    Methylation patterns in dysplasia in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2020 May 26:1-10. doi: 10.1080/00365521.2020.1766552.
    PubMed     Abstract available


  104. RASMUSSEN B, Haastrup P, Wehberg S, Kjeldsen J, et al
    Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy.
    Scand J Gastroenterol. 2020 May 22:1-8. doi: 10.1080/00365521.2020.1768282.
    PubMed     Abstract available


  105. KOTANI S, Fukuba N, Kawashima K, Mishima Y, et al
    Prevalence of functional dyspepsia-like symptoms in ulcerative colitis patients in clinical remission and overlap with irritable bowel syndrome-like symptoms.
    Scand J Gastroenterol. 2020 May 15:1-5. doi: 10.1080/00365521.2020.1761998.
    PubMed     Abstract available


    April 2020
  106. RONNBLOM A, Karlbom U
    Acute severe attacks of ulcerative colitis in a population-based cohort: epidemiology, treatment and outcome.
    Scand J Gastroenterol. 2020 Apr 27:1-5. doi: 10.1080/00365521.2020.1757143.
    PubMed     Abstract available


  107. ZHANG CC, Voitl R, Hippchen T, Weiss KH, et al
    Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis.
    Scand J Gastroenterol. 2020 Apr 24:1-7. doi: 10.1080/00365521.2020.1755357.
    PubMed     Abstract available


  108. VON VOLKMANN HL, Bronstad I, Tronstad RR, Dizdar V, et al
    Plasma levels of guanylins are reduced in patients with Crohn's disease.
    Scand J Gastroenterol. 2020 Apr 20:1-5. doi: 10.1080/00365521.2020.1748224.
    PubMed     Abstract available


  109. SHRESTHA S, Olen O, Eriksson C, Everhov AH, et al
    The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
    Scand J Gastroenterol. 2020;55:430-435.
    PubMed     Abstract available


  110. ZHAO L, Tang Y, Lei N, Zhou D, et al
    Clinical features and monocyte/macrophage subsets characterization in granulomatous vs non-granulomatous Crohn's disease.
    Scand J Gastroenterol. 2020;55:442-448.
    PubMed     Abstract available


  111. KRISTENSEN VA, Cvancarova M, Hoivik ML, Moum B, et al
    Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study.
    Scand J Gastroenterol. 2020;55:436-441.
    PubMed     Abstract available


  112. FREITAS M, Arieira C, Carvalho PB, Rosa B, et al
    Simplify to improve in capsule endoscopy - TOP 100 is a swift and reliable evaluation tool for the small bowel inflammatory activity in Crohn's disease.
    Scand J Gastroenterol. 2020;55:408-413.
    PubMed     Abstract available


    March 2020
  113. SOLBERG F, Ohlsson B
    Microscopic colitis and its associations with complications observed in classic inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2020 Mar 17:1-9. doi: 10.1080/00365521.2020.1739325.
    PubMed     Abstract available


  114. SOBOLEWSKA-WLODARCZYK A, Wlodarczyk M, Zielinska A, Siwinski P, et al
    Circadian rhythm abnormalities in patients with inflammatory bowel disease - association with adipokine profile.
    Scand J Gastroenterol. 2020 Mar 17:1-7. doi: 10.1080/00365521.2020.1737727.
    PubMed     Abstract available


  115. ZOU Y, Wu L, Xu W, Zhou X, et al
    Correlation between antibiotic use in childhood and subsequent inflammatory bowel disease: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2020 Mar 17:1-11. doi: 10.1080/00365521.2020.1737882.
    PubMed     Abstract available


  116. COENEN S, Nijns E, Weyts E, Geens P, et al
    Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy.
    Scand J Gastroenterol. 2020 Mar 17:1-7. doi: 10.1080/00365521.2020.1735506.
    PubMed     Abstract available


  117. MAK JWY, So J, Tang W, Yip TCF, et al
    Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Scand J Gastroenterol. 2020 Mar 2:1-8. doi: 10.1080/00365521.2020.1731760.
    PubMed     Abstract available


  118. ALULIS S, Vadstrup K, Borsi A, Nielsen A, et al
    Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Scand J Gastroenterol. 2020 Mar 2:1-7. doi: 10.1080/00365521.2020.1726445.
    PubMed     Abstract available


    February 2020
  119. GARSHOL BF, Aamodt G, Madsen C, Vatn MH, et al
    The effect of nitrogen dioxide on low birth weight in women with inflammatory bowel disease: a Norwegian pregnancy cohort study (MoBa).
    Scand J Gastroenterol. 2020 Feb 17:1-7. doi: 10.1080/00365521.2020.1726446.
    PubMed     Abstract available


  120. HOSSAIN A, Lordal M, Olsson AE, Storlahls A, et al
    Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease().
    Scand J Gastroenterol. 2020 Feb 13:1-6. doi: 10.1080/00365521.2020.1722738.
    PubMed     Abstract available


  121. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
    Altered body composition profiles in young adults with childhood-onset inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Feb 1:1-9. doi: 10.1080/00365521.2020.1716061.
    PubMed     Abstract available


  122. DAVIES M, Dodd S, Coultate M, Ross A, et al
    From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohn's disease.
    Scand J Gastroenterol. 2020;55:148-153.
    PubMed     Abstract available


    January 2020
  123. KIM ES, Lee HS, Kim SK, Kim EY, et al
    Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study.
    Scand J Gastroenterol. 2020 Jan 26:1-6. doi: 10.1080/00365521.2020.1714716.
    PubMed     Abstract available


  124. ANGELISON L, Almer S, Davidsdottir L, Hammarlund P, et al
    Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study.
    Scand J Gastroenterol. 2020 Jan 21:1-9. doi: 10.1080/00365521.2020.1713210.
    PubMed     Abstract available


  125. VADSTRUP K, Alulis S, Borsi A, Elkjaer Stallknecht S, et al
    Societal costs attributable to Crohn's disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002-2016.
    Scand J Gastroenterol. 2020 Jan 21:1-6. doi: 10.1080/00365521.2019.1707276.
    PubMed     Abstract available


  126. AMOUZADEH-GHADIKOLAI O, Reicht G, Quehenberger F, Robier C, et al
    Basophilia of the peripheral blood in patients with ulcerative colitis.
    Scand J Gastroenterol. 2020 Jan 12:1-3. doi: 10.1080/00365521.2019.1710247.
    PubMed     Abstract available


  127. ARKTEG CB, Goll R, Gundersen MD, Anderssen E, et al
    Mucosal gene transcription of ulcerative colitis in endoscopic remission.
    Scand J Gastroenterol. 2020 Jan 9:1-9. doi: 10.1080/00365521.2019.1710245.
    PubMed     Abstract available


  128. MOLANDER P, Kemppainen H, Ilus T, Sipponen T, et al
    Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases.
    Scand J Gastroenterol. 2020;55:34-40.
    PubMed     Abstract available


    December 2019
  129. PIGNICZKI D, Rutka M, Farkas K, Molnar T, et al
    Lupus-like reactions in patients with inflammatory bowel disease: a little bit different data from another center.
    Scand J Gastroenterol. 2019 Dec 9:1. doi: 10.1080/00365521.2019.1690038.
    PubMed    


  130. RYHLANDER J, Ringstrom G, Simren M, Stotzer PO, et al
    Undergoing repeated colonoscopies - experiences from patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Dec 9:1-6. doi: 10.1080/00365521.2019.1698649.
    PubMed     Abstract available


    November 2019
  131. YILMAZ KARADAG F, Arslan F, Caskurlu H, Cag Y, et al
    Efficacy of antiviral treatment in cytomegalovirus detected ulcerative colitis: meta-analysis of available data.
    Scand J Gastroenterol. 2019 Nov 13:1-7. doi: 10.1080/00365521.2019.1688860.
    PubMed     Abstract available


    October 2019
  132. SEGERMAN F, Clarkson S, Sjoberg K
    Marked regional variations in the prevalence of inflammatory bowel disease in a limited geographical region are not associated with compounds in the drinking water.
    Scand J Gastroenterol. 2019 Oct 15:1-11. doi: 10.1080/00365521.2019.1674374.
    PubMed     Abstract available


  133. AMCOFF K, Cao Y, Zhulina Y, Lampinen M, et al
    Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Oct 2:1-8. doi: 10.1080/00365521.2019.1670251.
    PubMed     Abstract available


    September 2019
  134. BODINI G, Demarzo MG, Saracco M, Coppo C, et al
    High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Sep 25:1-6. doi: 10.1080/00365521.2019.1666914.
    PubMed     Abstract available


  135. RIBALDONE DG, Vernero M, Parisi S, Ditto MC, et al
    Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients.
    Scand J Gastroenterol. 2019 Sep 24:1-4. doi: 10.1080/00365521.2019.1668052.
    PubMed     Abstract available


    March 2019
  136. BOTS SJ, Kuin S, Ponsioen CY, Gecse KB, et al
    Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Scand J Gastroenterol. 2019;54:281-288.
    PubMed     Abstract available


    February 2019
  137. KJAER MD, Qvist N, Nordgaard-Lassen I, Christensen LA, et al
    Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial.
    Scand J Gastroenterol. 2019;54:188-193.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: